GH Research PLC $GHRS Shares Bought by RA Capital Management L.P.

Key Points

• RA Capital Management L.P. increased its stake in GH Research PLC by 3.9%, owning 6,944,648 shares worth approximately $76.6 million, making it the company's 21st largest holding.
• GH Research recently reported earnings of ($0.15) per share, surpassing estimates, while analysts expect an average price target of $32.00 for the stock, with multiple ratings leaning towards a "Buy."
• The company's shares have ranged from a twelve month low of $6.00 to a high of $20.50, with an opening price of $13.50 observed recently.

RA Capital Management L.P. lifted its stake in GH Research PLC (NASDAQ:GHRS - Free Report) by 3.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,944,648 shares of the company's stock after purchasing an additional 257,959 shares during the quarter. GH Research comprises 1.3% of RA Capital Management L.P.'s portfolio, making the stock its 21st biggest holding. RA Capital Management L.P. owned about 13.35% of GH Research worth $76,599,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of GHRS. BNP Paribas Financial Markets purchased a new position in shares of GH Research in the 4th quarter worth approximately $44,000. Two Sigma Investments LP purchased a new position in shares of GH Research in the 4th quarter worth approximately $117,000. Palumbo Wealth Management LLC purchased a new position in shares of GH Research in the 1st quarter worth approximately $142,000. Millennium Management LLC purchased a new position in shares of GH Research in the 4th quarter worth approximately $145,000. Finally, XTX Topco Ltd purchased a new position in shares of GH Research in the 1st quarter worth approximately $169,000. Hedge funds and other institutional investors own 56.90% of the company's stock.

GH Research Stock Performance

NASDAQ GHRS traded up $0.04 on Friday, reaching $14.09. 245,365 shares of the stock traded hands, compared to its average volume of 195,288. The company has a fifty day moving average price of $14.18 and a 200-day moving average price of $12.12. The company has a market cap of $733.10 million, a price-to-earnings ratio of -19.04 and a beta of 0.97. GH Research PLC has a 12 month low of $6.00 and a 12 month high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. As a group, research analysts anticipate that GH Research PLC will post -0.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Wall Street Zen upgraded GH Research from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Zacks Research cut GH Research from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Guggenheim dropped their price objective on GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a report on Friday, May 9th. JMP Securities restated a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a report on Tuesday, June 24th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of GH Research in a report on Friday, May 9th. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $32.00.

GH Research Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).